Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Leerink Partners Downgrades Affimed Therapeutics (AFMD) to Market Perform
August 12, 2016 7:41 AM EDTLeerink Partners downgraded Affimed Therapeutics (NASDAQ: AFMD) from Outperform to Market Perform with a price target of $3.00 (from $8.00).
Analyst Michael Schmidt commented, "We are downgrading shares of AFMD to Market Perform, given that the company's two clinical stage product candidates are... More
Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign
August 10, 2016 7:36 AM EDTAffimed (NASDAQ: AFMD) reported Q2 EPS of (EUR0.24), EUR0.01 worse than the analyst estimate of (EUR0.23).
Affimed announced that the Companys Chief Medical Officer, Dr. Jens-Peter Marschner, has decided to step down as CMO. Since joining the Company in 2013, Dr. Marschner has... More
